Richard D. Truesdell, Jr.

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 46,000,000 shares of common stock of Plug Power Inc. for…

Davis Polk advised the initial purchasers in connection with an unregistered offering by AbbVie Inc. of $30 billion aggregate principal amount of senior notes, consisting of (i) $750…

Davis Polk advised MSCI Inc. in connection with a Rule 144A/Regulation S offering of an additional $500 million aggregate principal amount of its 4.000% senior notes due 2029. The…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 9,487,500 shares of common stock of…

Davis Polk advised the placement agents in connection with a private placement of shares of common stock of Applied Therapeutics, Inc. The aggregate proceeds of the private placement…

Davis Polk advised Centogene N.V. on its $56 million initial public offering of 4,000,000 of its common shares. In addition, Centogene has granted the underwriters a 30-day option to…

Davis Polk advised MSCI Inc. in connection with a Rule 144A/Regulation S offering of $500 million aggregate principal amount of its 4.000% senior notes due 2029. The notes are guaranteed by…

Davis Polk advised BRP Group, Inc. on its $229.6 million initial public offering of 16,400,000 shares of Class A common stock. The shares of Class A common stock are listed on the Nasdaq…

Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 4.250% senior notes…

Davis Polk advised the underwriters in connection with the $97.75 million initial public offering of 6,516,667 shares of common stock of Aprea Therapeutics, Inc., which includes 850,000…